Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma

Trial Profile

Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Selinexor (Primary) ; Dexamethasone; Doxorubicin liposomal
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2017 According to a Karyopharm Therapeutics media release, updated data from this trial will be presented at the American Society of Hematology (ASH) 2017 annual meeting.
    • 28 Jul 2017 Planned End Date changed from 1 Oct 2017 to 1 Jun 2019.
    • 28 Jul 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top